ArticleTheranostics2017
Overexpression of miR-194 Reverses HMGA2-driven Signatures in Colorectal Cancer.
Article in Theranostics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Expression of microRNA-99a-3p in Prostate Cancer Based on Bioinformatics Data and Meta-Analysis of a Literature Review of 965 Cases.Medical science monitor : international medical journal of experimental and clinical research · 2018Pooled it
- The multifaceted role of microRNAs in colorectal cancer: pathogenesis and therapeutic implications.Non-coding RNA research · 2025Review
- Diagnostic and Therapeutic Potential of Selected microRNAs in Colorectal Cancer: A Literature Review.Cancers · 2025Review
- Unraveling the Regulatory Role of HuR/microRNA Axis in Colorectal Cancer Tumorigenesis.Cancers · 2024Review
- HMGA2 promotes cancer metastasis by regulating epithelial-mesenchymal transition.Frontiers in oncology · 2024Review
- MEF2C and miR-194-5p: New Players in Triple Negative Breast Cancer Tumorigenesis.International journal of molecular sciences · 2023Article
- Novel biomarkers for neoplastic progression from ulcerative colitis to colorectal cancer: a systems biology approach.Scientific reports · 2023Article
- Recent advances microRNAs and metabolic reprogramming in colorectal cancer research.Frontiers in oncology · 2023Review
- Article
- Frailty in Aging and the Search for the Optimal Biomarker: A Review.Biomedicines · 2022Review
- MiR-194-3p modulates the progression of colorectal cancer by targeting KLK10.Histology and histopathology · 2022Article
- The Molecular Networks of microRNAs and Their Targets in the Drug Resistance of Colon Carcinoma.Cancers · 2021Review
- MicroRNA-Based Therapeutics for Drug-Resistant Colorectal Cancer.Pharmaceuticals (Basel, Switzerland) · 2021Review
- The Relationship Between the Network of Non-coding RNAs-Molecular Targets and N6-Methyladenosine Modification in Colorectal Cancer.Frontiers in cell and developmental biology · 2021Review
- Emerging roles for HMGA2 in colorectal cancer.Translational oncology · 2021Review
- Identification of the Effects of Aspirin and Sulindac Sulfide on the Inhibition of HMGA2-Mediated Oncogenic Capacities in Colorectal Cancer.Molecules (Basel, Switzerland) · 2020Article
- miRNA Clusters with Down-Regulated Expression in Human Colorectal Cancer and Their Regulation.International journal of molecular sciences · 2020Review
- The role of NMolecular cancer · 2020Review
- MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer.World journal of gastroenterology · 2020Article
- Screening and functional prediction of differentially expressed circRNAs in proliferative human aortic smooth muscle cells.Journal of cellular and molecular medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the leading causes of cancer death worldwide with increasing incidence and mortality in developed countries. Oncogenes and microRNAs regulate key signaling pathways in CRC and are known to be deregulated. Oncogenic transcriptional regulator high-mobility group AT-hook 2 (HMGA2) participates in the transformation of several cancers including CRC and exhibits strong correlation with poor prognosis and distal metastasis. Evidence of HMGA2 and its co-regulated miRs contributing to tumor progression remains to be clarified.
methodsWe performed gene-set enrichment analysis on the expression profiles of 70 CRC patients and revealed HMGA2 correlated genes that are targeted by several miRs including miR-194. To eliminate the oncogenic effects in HMGA2-driven CRC, we re-expressed miR-194 and found that miR-194 functions as a tumor suppressor by reducing cell proliferation and tumor growth
resultsAs a direct upstream inhibitory regulator of miR-194, overexpression of HMGA2 reduced miR-194 expression and biological activity, whereas re-expressing miR-194 in cells with high levels of HMGA2 impaired the effects of HMGA2, compromising cell survival, the epithelial-mesenchymal transition process, and drug resistance.
conclusionOur findings demonstrate that novel molecular correlations can be discovered by revisiting transcriptome profiles. We uncover that miR-194 is as important as HMGA2, and both coordinately regulate the oncogenesis of CRC with inverted behaviors, revealing alternative molecular therapeutics for CRC patients with high HMGA2 expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.